Dirk Jäger
About
Dirk Jäger is a scholar working on Oncology, Immunology and Molecular Biology.
According to data from OpenAlex, Dirk Jäger has authored 120 papers receiving a total of 5.9k indexed citations (citations by other indexed papers that have themselves been cited), including 66 papers in Oncology, 37 papers in Immunology and 31 papers in Molecular Biology. Recurrent topics in Dirk Jäger's work include Immunotherapy and Immune Responses (30 papers), Cancer Immunotherapy and Biomarkers (23 papers) and Colorectal Cancer Treatments and Studies (20 papers). Dirk Jäger is often cited by papers focused on Immunotherapy and Immune Responses (30 papers), Cancer Immunotherapy and Biomarkers (23 papers) and Colorectal Cancer Treatments and Studies (20 papers). Dirk Jäger collaborates with scholars based in Germany, United States and France. Dirk Jäger's co-authors include Alexander Knuth, Elke Jäger, Jürgen Debus, Frederik L. Giesel, Walter Mier, Thomas Lindner, Clemens Kratochwil, Uwe Haberkorn, Annette Altmann and Anastasia Loktev and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Journal of Clinical Oncology.
In The Last Decade
Dirk Jäger
113 papers receiving 5.8k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Dirk Jäger Germany | 35 | 3.5k | 1.9k | 1.7k | 1.4k | 1.3k | 120 | 5.9k | ||
| R. Katherine Alpaugh United States | 37 | 2.6k 0.7× | 1.1k 0.6× | 1.7k 1.0× | 314 0.2× | 859 0.6× | 112 | 4.5k | ||
| Andrea T. Hooper United States | 32 | 2.6k 0.8× | 1.0k 0.5× | 2.8k 1.6× | 298 0.2× | 1.2k 0.9× | 56 | 5.8k | ||
| Martina Mirlacher Switzerland | 39 | 2.5k 0.7× | 560 0.3× | 2.2k 1.3× | 656 0.5× | 1.1k 0.9× | 62 | 5.3k | ||
| Christina Addison Canada | 34 | 2.5k 0.7× | 1.6k 0.8× | 2.1k 1.2× | 400 0.3× | 674 0.5× | 89 | 5.2k | ||
| Michael A. Curran United States | 35 | 4.0k 1.1× | 3.6k 1.9× | 1.7k 1.0× | 438 0.3× | 867 0.7× | 127 | 7.0k | ||
| Ann H. Klopp United States | 41 | 2.3k 0.7× | 522 0.3× | 1.6k 0.9× | 1.3k 0.9× | 991 0.7× | 199 | 6.5k | ||
| Masayuki Miyake Japan | 41 | 1.8k 0.5× | 962 0.5× | 2.2k 1.3× | 288 0.2× | 676 0.5× | 79 | 4.4k | ||
| Richard L. Shapiro United States | 38 | 2.5k 0.7× | 1.1k 0.6× | 2.4k 1.4× | 720 0.5× | 1.6k 1.2× | 142 | 5.2k | ||
| Alessandro M. Gianni Italy | 44 | 3.7k 1.1× | 2.1k 1.1× | 2.1k 1.2× | 1.3k 0.9× | 703 0.5× | 205 | 9.4k | ||
| Albrecht Neeße Germany | 29 | 3.8k 1.1× | 1.1k 0.6× | 1.9k 1.1× | 957 0.7× | 1.3k 1.0× | 126 | 5.9k |
Countries citing papers authored by Dirk Jäger
Since
Specialization
Citations
This map shows the geographic impact of Dirk Jäger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dirk Jäger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dirk Jäger more than expected).
Fields of papers citing papers by Dirk Jäger
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Dirk Jäger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dirk Jäger. The network helps show where Dirk Jäger may publish in the future.
Co-authorship network of co-authors of Dirk Jäger
This figure shows the co-authorship network connecting the top 25 collaborators of Dirk Jäger. A scholar is included among the top collaborators of Dirk Jäger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dirk Jäger. Dirk Jäger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Schmitt, Nathalie, James M. Robl, Katja Mehlis, et al.. (2025). Optimization of multiprofessional care for young colorectal cancer patients: a qualitative Study. The Oncologist. 30(5).
2.
Kobitski, Andrei Yu, Matthias Schulz, Oksana Voloshanenko, et al.. (2025). WNT5a export onto extracellular vesicles studied at single‐molecule and single‐vesicle resolution. FEBS Journal. 292(17). 4631–4649.
3.
Ziener, Christian H., Jennifer Hüllein, Jörg Richter, et al.. (2025). Monitoring soluble cMET and ctDNA in metastatic uveal melanoma patients to track early disease progression on immunotherapies. Journal of Experimental & Clinical Cancer Research. 44(1). 213–213.
4.
Schütz, Viktoria, Anette Duensing, Stefanie Zschäbitz, et al.. (2024). Improved survival of patients with newly diagnosed oligometastatic prostate cancer through intensified multimodal treatment. Frontiers in Oncology. 14. 1475914–1475914.
5.
Helisch, Andreas, Clemens Kratochwil, Christian Kleist, et al.. (2024). Feasibility, Tolerability, and Preliminary Clinical Response of Fractionated Radiopharmaceutical Therapy with213Bi-FAPI-46: Pilot Experience in Patients with End-Stage, Progressive Metastatic Tumors. Journal of Nuclear Medicine. 65(12). jnumed.124.268386–jnumed.124.268386.
6.
Le, Dung T., Luis A. Díaz, Tae Won Kim, et al.. (2023). Pembrolizumab for previously treated, microsatellite instability–high/mismatch repair–deficient advanced colorectal cancer: final analysis of KEYNOTE-164. European Journal of Cancer. 186. 185–195.
7.
Fremd, Carlo, Mario Hlevnjak, Marc Zapatka, et al.. (2018). Mismatch Repair Deficiency Drives Durable Complete Remission by Targeting Programmed Death Receptor 1 in a Metastatic Luminal Breast Cancer Patient. Breast Care. 14(1). 53–59.
8.
Ott, Patrick A., Dung T. Le, Paolo A. Ascierto, et al.. (2017). Nivolumab (NIVO) in patients (pts) with advanced (adv) chemotherapy-refractory (CT-Rx) esophagogastric (EG) cancer according to microsatellite instability (MSI) status: checkmate 032. Annals of Oncology. 28. v229–v230.
9.
Haag, Georg Martin, et al.. (2017). Perioperative Chemotherapy in Elderly Patients with Locally Advanced Adenocarcinoma of the Stomach and the Esophagogastric Junction: A Retrospective Cohort Analysis of Toxicity and Efficacy at the National Center for Tumor Diseases, Heidelberg. Oncology. 92(5). 291–298.
10.
Reißfelder, Christoph, Slava Stamova, Marion Braun, et al.. (2014). Tumor-specific cytotoxic T lymphocyte activity determines colorectal cancer patient prognosis. Journal of Clinical Investigation. 125(2). 739–751.
11.
Potthoff, Karin, Gregor Habl, Thomas Brückner, et al.. (2014). Randomized controlled trial to evaluate the effects of ethyl-2-cyanoacrylate on pain intensity and quality of life in head and neck cancer patients suffering from cetuximab-induced rhagades during radioimmunotherapy: the support trial. BMC Cancer. 14(1). 270–270.
12.
Blank, Susanne, Florian Lordick, Martin Dobritz, et al.. (2013). A reliable risk score for stage IV esophagogastric cancer. European Journal of Surgical Oncology. 39(8). 823–830.
13.
Lorenzen, Sylvie, Georg Martin Haag, Jürgen Weitz, et al.. (2011). Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): The Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial. BMC Cancer. 11(1). 266–266.
14.
Halama, Niels, Inka Zoernig, & Dirk Jäger. (2008). Immuntherapie von Tumoren – Moderne immunologische Strategien in der Onkologie. DMW - Deutsche Medizinische Wochenschrift. 133(41). 2105–2108.
15.
Lordick, Florian, Katja Ott, Jürgen Weitz, & Dirk Jäger. (2008). The evolving role of catumaxomab in gastric cancer. Expert Opinion on Biological Therapy. 8(9). 1407–1415.
16.
Zhu, Yifan, Thilo Hackert, Eduard Ryschich, et al.. (2008). Interferon-α in Combination With Chemotherapy has Potent Antiangiogenic Properties in an Orthotopic Mouse Model for Pancreatic Adenocarcinoma. Journal of Immunotherapy. 31(1). 28–33.
17.
Pestalozzi, Bernhard C., Dirk Jäger, & Alexander Knuth. (2005). Systemtherapie des kolorektalen Karzinoms. Der Chirurg. 76(6). 570–574.
18.
Westermann, Anneke M., G. Wiedemann, Elke Jäger, et al.. (2003). A Systemic Hyperthermia Oncologic Working Group Trial. Oncology. 64(4). 312–321.
19.
Scanlan, Matthew J., Claudia Gordon, Barbara Williamson, et al.. (2002). Identification of cancer/testis genes by database mining and mRNA expression analysis. International Journal of Cancer. 98(4). 485–492.
20.
Knuth, Alexander, Dirk Jäger, & Elke Jäger. (2000). Cancer immunotherapy in clinical oncology. Cancer Chemotherapy and Pharmacology. 46(S1). S46–S51.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by R. Katherine Alpaugh Breakdown of academic impact, for papers by Andrea T. Hooper Breakdown of academic impact, for papers by Martina Mirlacher Breakdown of academic impact, for papers by Christina Addison Breakdown of academic impact, for papers by Michael A. Curran Breakdown of academic impact, for papers by Ann H. Klopp Breakdown of academic impact, for papers by Masayuki Miyake Breakdown of academic impact, for papers by Richard L. Shapiro Breakdown of academic impact, for papers by Alessandro M. Gianni Breakdown of academic impact, for papers by Albrecht Neeße